These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 18054408

  • 1. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD.
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T, Thatcher N, Leyvraz S, Miller WH, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M.
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T, Thomas J, Miller WH, Gore M, Wolter P, Kavan P, Martín JA, Lardelli P.
    Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma.
    Baudin E, Droz JP, Paz-Ares L, van Oosterom AT, Cullell-Young M, Schlumberger M.
    Am J Clin Oncol; 2010 Feb; 33(1):83-8. PubMed ID: 19704366
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
    Wibmer T, Kropf C, Merk T, Schumann C, Hombach V, Krüger S.
    Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
    [Abstract] [Full Text] [Related]

  • 6. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V, Gebbia V, Spada M, Guida M, Cassano G, Brunetti C, Germano D, Nettis G, Izzi G, Galetta D, Giampaglia M, Silvestris N, Colucci G.
    Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J.
    J Clin Oncol; 2009 Aug 10; 27(23):3836-41. PubMed ID: 19597027
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.
    Lung Cancer; 2009 Jun 10; 64(3):319-25. PubMed ID: 19095327
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2008 Sep 10; 61(3):369-77. PubMed ID: 18308419
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL, Gregorc V, Cordio S, Bencardino KB, Schipani S, Cozzarini C, Bordonaro R, Villa E.
    Lung Cancer; 2004 May 10; 44(2):231-9. PubMed ID: 15084388
    [Abstract] [Full Text] [Related]

  • 11. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fractionated dose of cisplatin (CDDP) and vinorelbine (VNB) chemotherapy for elderly patients with advanced non-small cell lung cancer: phase II trial.
    Buffoni L, Dongiovanni D, Barone C, Fissore C, Ottaviani D, Dongiovanni V, Grillo R, Salvadori A, Birocco N, Schena M, Bertetto O.
    Lung Cancer; 2006 Dec 20; 54(3):353-7. PubMed ID: 17049672
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
    Giorgio CG, Pappalardo A, Russo A, Santini D, Di Rosa C, Di Salvo C, Castorina S, Marletta F, Bellissima G, Palermo N, Scuderi C, Bordonaro R.
    Anticancer Drugs; 2007 Jul 20; 18(6):713-9. PubMed ID: 17762402
    [Abstract] [Full Text] [Related]

  • 15. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
    Fischer JR, Griesinger F, Fink T, Salm T, Marseille A, Wolf M.
    Lung Cancer; 2012 Mar 20; 75(3):348-52. PubMed ID: 21908069
    [Abstract] [Full Text] [Related]

  • 16. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Surmont V, Aerts JG, Pouw E, Tan KY, Vernhout R, Gras J, Salomé J, Pronk T, Schmitz PI, Hoogsteden H, van Klaveren RJ.
    Lung Cancer; 2009 Dec 20; 66(3):333-7. PubMed ID: 19327865
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
    Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R.
    Lung Cancer; 2010 Apr 20; 68(1):89-93. PubMed ID: 19524318
    [Abstract] [Full Text] [Related]

  • 18. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.
    J Clin Oncol; 2009 Sep 10; 27(26):4274-80. PubMed ID: 19652055
    [Abstract] [Full Text] [Related]

  • 19. Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial.
    Stathopoulos GP, Dimitroulis J, Toubis M, Katis C, Karaindros D, Stathopoulos J, Koutandos J.
    Lung Cancer; 2007 Jul 10; 57(1):66-71. PubMed ID: 17382431
    [Abstract] [Full Text] [Related]

  • 20. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G.
    Clin Lung Cancer; 2008 Sep 10; 9(5):280-4. PubMed ID: 18824450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.